COVID-19 vaccination showed effectiveness in reducing hospitalizations and severe disease outcomes associated with the SARS-CoV-2 JN.1 lineage, according to a recent study published in JAMA Network ...
Moderna's mRNA-1010 flu vaccine for older adults could be made available by the end of 2026, the pharmaceutical company announced on Friday.
Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups Both of Moderna’s COVID-19 vaccines for the ...
Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results